Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Net Margin % : 0.00% (As of Dec. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Eucrates Biomedical Acquisition Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Eucrates Biomedical Acquisition's Net Income for the three months ended in Dec. 2022 was $0.14 Mil. Eucrates Biomedical Acquisition's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, Eucrates Biomedical Acquisition's net margin for the quarter that ended in Dec. 2022 was 0.00%.

The historical rank and industry rank for Eucrates Biomedical Acquisition's Net Margin % or its related term are showing as below:

EUCRU's Net Margin % is not ranked ^*
in the Diversified Financial Services industry.
Industry Median: 4.5
* Ranked among companies with meaningful Net Margin % only.

Eucrates Biomedical Acquisition Net Margin % Historical Data

The historical data trend for Eucrates Biomedical Acquisition's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eucrates Biomedical Acquisition Net Margin % Chart

Eucrates Biomedical Acquisition Annual Data

Trend

Dec20

Dec21

Dec22

Net Margin %

Eucrates Biomedical Acquisition Quarterly Data
	Aug20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Net Margin %	Get a 7-Day Free Trial					-	-	-	-	-

Competitive Comparison of Eucrates Biomedical Acquisition's Net Margin %

For the Shell Companies subindustry, Eucrates Biomedical Acquisition's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eucrates Biomedical Acquisition's Net Margin % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Eucrates Biomedical Acquisition's Net Margin % distribution charts can be found below:

* The bar in red indicates where Eucrates Biomedical Acquisition's Net Margin % falls into.

Eucrates Biomedical Acquisition Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Eucrates Biomedical Acquisition's Net Margin for the fiscal year that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	2.42	/	0
	=	%

Eucrates Biomedical Acquisition's Net Margin for the quarter that ended in Dec. 2022 is calculated as

Net Margin	=	Net Income (Q: Dec. 2022 )	/	Revenue (Q: Dec. 2022 )
	=	0.142	/	0
	=	%

Eucrates Biomedical Acquisition (NAS:EUCRU) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Eucrates Biomedical Acquisition Net Margin % Related Terms

Thank you for viewing the detailed overview of Eucrates Biomedical Acquisition's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Eucrates Biomedical Acquisition Corp (NAS:EUCRU) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

250 West 55th Street, Suite 13D, New York, NY, USA, 10019

Website

Eucrates Biomedical Acquisition Corp is a blank check company.

Executives

Stelios Papadopoulos	director, 10 percent owner	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
William I Campbell	director	270 PARK AVENUE, NEW YORK NY 10017
Nina B. Shapiro	director	2201 WALNUT AVENUE, SUITE 100, FREMONT CA 94538
Parag Saxena	director, 10 percent owner, officer: Chief Executive Officer	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Daphne Karydas	director	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Atanuu Agarrwal	officer: Vice President	250 WEST 55TH STREET, NEW YORK NY 10019
Gonzalo Cordova	officer: Chief Financial Officer	250 WEST 55TH STREET, NEW YORK NY 10019
Eucrates Llc	10 percent owner	250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Shrikant Sathe	officer: Senior Vice President	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Evangelos Vergetis	director, officer: President, COO	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Amitabh Singhal	director	C/O EUCRATES LLC, 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019

Eucrates Biomedical Acquisition (Eucrates Biomedical Acquisition) Headlines

From GuruFocus

Eucrates Biomedical Acquisition Corp. Announces Closing Of $100 Million Initial Public Offering

By PRNewswire PRNewswire • 10-28-2020

Eucrates Biomedical Acquisition Corp. Receives Expected Notice From Nasdaq Regarding Delayed Quarterly Report

By PRNewswire PRNewswire • 06-01-2021

Eucrates Biomedical Acquisition Corp. Announces Liquidation

By PRNewswire PRNewswire • 04-11-2023